Antizyme Inhibitor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 22: Line 22:
{{Clear}}
{{Clear}}
-
<applet load="3BTN.pdb" size="300" color="white" frame="true" align="left" scene='Antizyme_Inhibitor/Azi/1' spinBox="true" />
+
<StructureSection load="3BTN.pdb" size="500" color="white" frame="true" align="right" scene='Antizyme_Inhibitor/Azi/1' spinBox="true" >
Each <scene name='Antizyme_Inhibitor/Monomer/5'>monomer</scene> consists of two domains: a <scene name='Antizyme_Inhibitor/Monomer/6'>TIM-like</scene> α/β-barrel [http://en.wikipedia.org/wiki/TIM_barrel] domain (residues 45–280) and a modified <scene name='Antizyme_Inhibitor/Monomer/7'>Greek key</scene> [http://en.wikipedia.org/wiki/Greek_key] β-sheet domain (residues 8–44 and 281–435). <font color='red'><b>Helices</b></font> [http://en.wikipedia.org/wiki/Alpha_helix] are colored in <font color='red'><b>red</b></font> and <font color='black'><b>β sheets</b></font> [http://en.wikipedia.org/wiki/Beta_sheet] in <font color='black'><b>yellow</b></font>.
Each <scene name='Antizyme_Inhibitor/Monomer/5'>monomer</scene> consists of two domains: a <scene name='Antizyme_Inhibitor/Monomer/6'>TIM-like</scene> α/β-barrel [http://en.wikipedia.org/wiki/TIM_barrel] domain (residues 45–280) and a modified <scene name='Antizyme_Inhibitor/Monomer/7'>Greek key</scene> [http://en.wikipedia.org/wiki/Greek_key] β-sheet domain (residues 8–44 and 281–435). <font color='red'><b>Helices</b></font> [http://en.wikipedia.org/wiki/Alpha_helix] are colored in <font color='red'><b>red</b></font> and <font color='black'><b>β sheets</b></font> [http://en.wikipedia.org/wiki/Beta_sheet] in <font color='black'><b>yellow</b></font>.
{{Clear}}
{{Clear}}
- 
-
<applet load="AzIODCali.pdb" size="500" color="white" frame="true" align="right" scene='Antizyme_Inhibitor/Azi_odc/1' spinBox="true" />
 
Line 35: Line 33:
{{Clear}}
{{Clear}}
-
<applet load="AzIODCplp.pdb" size="500" color="white" frame="true" align="right" scene='Antizyme_Inhibitor/Binding_site/5' spinBox="true" />
+
<scene name='Antizyme_Inhibitor/Binding_site/6'>Overlap</scene> of the AzI and mODC structures suggests that AzI does not bind [http://en.wikipedia.org/wiki/Pyridoxal_phosphate PLP]. <font color='black'><b>PLP</b></font> is in <font color='black'><b>yellow</b></font>, <font color='lime'><b>ODC residues D88, R154, R277, and Y389 are in lime</b></font>, and the corresponding <font color='magenta'><b>AzI residues A88, H154, S274, and D387 are in magenta</b></font>. Many of the residues participating in PLP-ODC binding are not conserved in AzI. These include D88A, R154H, R277S, D332E, and Y389D (ODC residue numbers follow the sequence of AzI). Notably, the absence of even one of these interactions, (''e.g.'' ODC R277A mutant) results in a 100-fold decrease in PLP binding, a 50% drop in K<sub>cat</sub>, and a 7-fold decrease in K<sub>M</sub>.
 +
</StructureSection>
- 
-
<scene name='Antizyme_Inhibitor/Binding_site/6'>Overlap</scene> of the AzI and mODC structures suggests that AzI does not bind [http://en.wikipedia.org/wiki/Pyridoxal_phosphate PLP]. <font color='black'><b>PLP</b></font> is in <font color='black'><b>yellow</b></font>, <font color='lime'><b>ODC residues D88, R154, R277, and Y389 are in lime</b></font>, and the corresponding <font color='magenta'><b>AzI residues A88, H154, S274, and D387 are in magenta</b></font>. Many of the residues participating in PLP-ODC binding are not conserved in AzI. These include D88A, R154H, R277S, D332E, and Y389D (ODC residue numbers follow the sequence of AzI). Notably, the absence of even one of these interactions, (''e.g.'' ODC R277A mutant) results in a 100-fold decrease in PLP binding, a 50% drop in K<sub>cat</sub>, and a 7-fold decrease in K<sub>M</sub>.
 
==Additional Resources==
==Additional Resources==

Revision as of 13:31, 13 January 2011

Crystal structure of the Antizyme inhibitor

PDB ID 3BTN.pdb

Drag the structure with the mouse to rotate
AzI, 3BTN
Coordinates: save as pdb, mmCIF, xml



Publication Abstract from PubMed

Antizyme inhibitor (AzI) regulates cellular polyamine homeostasis by binding to the polyamine-induced protein, Antizyme (Az), with greater affinity than ornithine decarboxylase (ODC). AzI is highly homologous to ODC but is not enzymatically active. In order to understand these specific characteristics of AzI and its differences from ODC, we determined the 3D structure of mouse AzI to 2.05 A resolution. Both AzI and ODC crystallize as a dimer. However, fewer interactions at the dimer interface, a smaller buried surface area, and lack of symmetry of the interactions between residues from the two monomers in the AzI structure suggest that this dimeric structure is nonphysiological. In addition, the absence of residues and interactions required for pyridoxal 5'-phosphate (PLP) binding suggests that AzI does not bind PLP. Biochemical studies confirmed the lack of PLP binding and revealed that AzI exists as a monomer in solution while ODC is dimeric. Our findings that AzI exists as a monomer and is unable to bind PLP provide two independent explanations for its lack of enzymatic activity and suggest the basis for its enhanced affinity toward Az.

Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function., Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C, Protein Sci. 2008 May;17(5):793-802. Epub 2008 Mar 27. PMID:18369191

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


PDB ID 3BTN.pdb

Drag the structure with the mouse to rotate


Additional Resources

For additional information, see: Cancer

Reference

Shira Albeck, Orly Dym, Tamar Unger, Zohar Snapir, Zippy Bercovich and Chaim Kahana. Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 2008 May; 17(5): 793-802. Epub 2008 Mar 27.

Personal tools